Simple Urine Test Could Detect Multiple Cancers at Early Stage

Now, a spectroscopy and artificial intelligence (AI)-powered urine-based test uses scent-based technology for the routine and noninvasive detection of cancer-related VOCs.

TOBY, Inc. (New York City, NY, USA) has developed a single urine test that detects 10 cancers, representing over 60% of all new cases globally. This test identifies the unique molecular signature of cancer by combining the precision of spectroscopy, changes in biomarkers (VOCs), and cutting-edge computational algorithms to deliver early, easy, and affordable cancer screening. The process begins with spectroscopy, analyzing the molecular signature of VOCs in urine. These signatures reflect real-time changes in physiology and metabolism. The company’s proprietary AI interprets this complex data to identify early patterns of disease, often before symptoms appear. These algorithms are the result of deep research, development, and training on diverse biological signatures. Every model is engineered to learn from high-dimensional data, capturing subtle, disease-specific patterns with remarkable precision.

Unlike traditional diagnostics that rely on imaging or genetic sequencing, this test focuses on what the body emits in the moment. This approach is fast, scalable, and noninvasive—offering a new pathway for early detection across multiple cancer types. Instead of just detecting cancer, the test interprets the body’s chemical signals using a single, simple urine sample and turns them into actionable insights. TOBY combine truly noninvasive sampling, advanced spectroscopy, and AI for a uniquely accurate, accessible cancer test for multiple cancers.

"Our goal is to support earlier detection, when treatment is most effective and the burden on patients and the healthcare system is reduced," said Dragan Sebišanović, Chief Science Officer of TOBY. "Our technology uses machine learning to help identify molecular patterns associated with early-stage cancer."

Related Links:
TOBY, Inc.